Background Maintenance therapy with imatinib through the post-transplant period has been used for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph?+?ALL); however, its efficacy has not been demonstrated. 3C4 adverse events (AEs) occurred in 17.7% of patients. Ten patients (16.1%) terminated imatinib therapy owing to AEs. Among the patients in imatinib and non-imatinib groups, the… Continue reading Background Maintenance therapy with imatinib through the post-transplant period has been